Canaccord Genuity Group Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price

Eton Pharmaceuticals (NASDAQ:ETON) had its price target upped by Canaccord Genuity Group from $68.00 to $80.00 in a research note released on Friday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

A number of other equities analysts have also recently weighed in on ETON. Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. Weiss Ratings upgraded shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. HC Wainwright raised their price objective on shares of Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Friday. Craig Hallum reaffirmed a “buy” rating and set a $78.00 price target on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. Finally, B. Riley Financial reissued a “buy” rating and issued a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $77.00.

Eton Pharmaceuticals Stock Up 19.7%

Shares of NASDAQ:ETON traded up $9.31 during midday trading on Friday, hitting $56.46. 1,269,987 shares of the company’s stock traded hands, compared to its average volume of 435,252. The firm’s fifty day moving average price is $54.80 and its two-hundred day moving average price is $36.46. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. Eton Pharmaceuticals has a twelve month low of $14.27 and a twelve month high of $66.37. The company has a market cap of $1.61 billion, a PE ratio of 37.39 and a beta of 0.89.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.31 by $0.19. The firm had revenue of $57.93 million for the quarter, compared to analyst estimates of $41.98 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. On average, equities research analysts anticipate that Eton Pharmaceuticals will post 1.13 EPS for the current fiscal year.

Insider Buying and Selling at Eton Pharmaceuticals

In related news, insider David Krempa sold 25,000 shares of Eton Pharmaceuticals stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $65.07, for a total value of $1,626,750.00. Following the sale, the insider directly owned 37,025 shares in the company, valued at $2,409,216.75. This trade represents a 40.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $59.07, for a total value of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares in the company, valued at approximately $3,529,137.15. This represents a 45.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 79,166 shares of company stock valued at $4,809,672. Corporate insiders own 16.49% of the company’s stock.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several institutional investors have recently bought and sold shares of ETON. Toth Financial Advisory Corp lifted its stake in shares of Eton Pharmaceuticals by 41.7% in the 3rd quarter. Toth Financial Advisory Corp now owns 1,700 shares of the company’s stock worth $88,000 after acquiring an additional 500 shares during the period. Hilton Head Capital Partners LLC acquired a new stake in shares of Eton Pharmaceuticals in the third quarter valued at $26,000. Sterling Capital Management LLC lifted its holdings in Eton Pharmaceuticals by 845.7% in the 3rd quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock valued at $46,000 after acquiring an additional 795 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Eton Pharmaceuticals by 19.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,215 shares of the company’s stock worth $269,000 after purchasing an additional 855 shares in the last quarter. Finally, SBI Securities Co. Ltd. lifted its stake in Eton Pharmaceuticals by 159.0% during the third quarter. SBI Securities Co. Ltd. now owns 1,852 shares of the company’s stock valued at $95,000 after purchasing an additional 1,137 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

Key Stories Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Q3 product sales reached a record $57.9 million, up 158% year over year. Eton reported diluted GAAP EPS of $1.06 and non-GAAP EPS of $0.50, and said it exceeded a $200 million annualized revenue run rate five quarters ahead of schedule. Eton Q3 results
• Positive Sentiment: Management raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to above 40%, from above 35%. The stronger forecast reinforces expectations for continued growth and improving profitability. Eton earnings and guidance
• Positive Sentiment: Canaccord Genuity and HC Wainwright both raised their price targets to $80 and maintained Buy ratings, signaling confidence in Eton’s prospects. Canaccord Genuity rating HC Wainwright rating
• Neutral Sentiment: Eton announced preliminary results from an ET-700 pilot study assessing copper absorption inhibition and gastrointestinal tolerability. The brief report does not provide enough detail to judge the findings’ significance for the pipeline. ET-700 pilot study update

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.